Pliant Therapeutics, Inc.

NASDAQ:PLRX

Biotechnology

Healthcare
$0.81 -3.39%

-$0.04 today

Market cap
$50.14M
Beta
1.21
P/E (TTM)
-0.6
EPS (TTM)
-$1.83
52W Low $1.09High $1.95

Volume 0.15M

Average 0.49M

PLRX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Pliant Therapeutics, Inc.NASDAQ: PLRX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$19.78M, compared with -$54.92M a year earlier. Trailing-twelve-month EBITDA was -$107.98M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of -$83.83M (+42.2%) for the fiscal year ending Dec 2026, a step up from the +29.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.78M+14.3% QoQ
Last fiscal yearDec 2025
-$145.09M+29.3% YoY
LTMMar 2026
-$107.98M+49.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+64.0%——
1 year+29.3%+42.2%+12.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(145.09M) USD
Year-over-year change
+29.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PLRX compares with its peers on the latest reported figures

  • PLRX's LTM Mar 2026 EBITDA of -$107.98M is the 8th highest of the 10 companies compared; the peer median is -$84.44M.
  • Its year-over-year change of +49.6% is the highest of 10, against a peer median of -18.3%.
PLRX Competitors Peer median
EBITDA for PLRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COYACoya Therapeutics, Inc.LTM Mar 2026-$21.1M -18.3%—265.8%
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24M +7.8%—337.0%
CLNNClene Inc.LTM Mar 2026-$29.2M -21.6%—21792.5%
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M -7.0%—32.2%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$84.44M -35.4%——
STROSutro Biopharma, Inc.LTM Mar 2026-$106.12M +42.0%—106.5%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$106.88M -21.2%——
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$107.98M +49.6%——
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$115.78M -490.7%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$130.98M +37.9%——
Peer median (excluding PLRX) -$84.44M-18.3%—265.8%

Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.57M9.69M1.58M00
Cost of Revenue00001.7M
Gross Profit7.57M9.69M1.58M0(1.7M)
Gross Margin100.0%100.0%100.0%——
Research & Development77.55M96.94M127.8M169.31M109.16M
Selling, General & Admin27.56M39.95M57.93M59.06M47.22M
Operating Expenses105.11M136.89M185.73M228.37M148.38M
Depreciation & Amortization1.54M3.68M1.84M2.13M1.7M
EBITDA(95.73M)(118.85M)(158.23M)(205.16M)(145.09M)
EBITDA Margin-1264.2%-1227.1%-10014.4%——
Operating Income(97.54M)(127.2M)(184.15M)(228.37M)(150.07M)
Operating Margin-1288.1%-1313.4%-11654.7%——
Interest Income272K4.67M24.08M21.09M0
Interest Expense0791K1.27M3.02M2.56M
Other Income / Expenses272K3.88M22.81M18.06M729K
Income Before Tax(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Pre-Tax Margin-1284.5%-1273.3%-10211.1%——
Income Tax Expense00000
Net Income(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Net Margin-1284.5%-1273.3%-10211.1%——
EPS (Basic)(2.71)(2.94)(2.75)(3.47)(2.43)
EPS (Diluted)(2.71)(2.94)(2.75)(3.47)(2.43)
Weighted Avg Shares35.85M42.02M58.72M60.54M61.37M
Weighted Avg Shares (Diluted)35.85M42.02M58.72M60.54M61.37M

Pliant Therapeutics, Inc.

NASDAQ:PLRX

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.